[go: up one dir, main page]

CA2400205A1 - Modification de biopolymeres pour administration amelioree de medicaments - Google Patents

Modification de biopolymeres pour administration amelioree de medicaments Download PDF

Info

Publication number
CA2400205A1
CA2400205A1 CA002400205A CA2400205A CA2400205A1 CA 2400205 A1 CA2400205 A1 CA 2400205A1 CA 002400205 A CA002400205 A CA 002400205A CA 2400205 A CA2400205 A CA 2400205A CA 2400205 A1 CA2400205 A1 CA 2400205A1
Authority
CA
Canada
Prior art keywords
biopolymer
group
conjugate
therapeutic agent
chemically modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002400205A
Other languages
English (en)
Inventor
Pericles Calias
Robert J. Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2400205A1 publication Critical patent/CA2400205A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

L'invention concerne un conjugué biologiquement actif, qui contient un biopolymère et un agent thérapeutique réunis par une liaison disulfure. Le conjugué, formulé en une composition pharmaceutique avec un excipient approprié, possède une stabilité et une activité in vivo accrues et peut être ciblé sur diverses cellules, divers tissus et organes.
CA002400205A 2000-02-15 2001-02-15 Modification de biopolymeres pour administration amelioree de medicaments Abandoned CA2400205A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18255800P 2000-02-15 2000-02-15
US60/182,558 2000-02-15
US21150800P 2000-06-14 2000-06-14
US60/211,508 2000-06-14
PCT/US2001/004925 WO2001060412A2 (fr) 2000-02-15 2001-02-15 Modification de biopolymeres pour administration amelioree de medicaments

Publications (1)

Publication Number Publication Date
CA2400205A1 true CA2400205A1 (fr) 2001-08-23

Family

ID=26878197

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002400205A Abandoned CA2400205A1 (fr) 2000-02-15 2001-02-15 Modification de biopolymeres pour administration amelioree de medicaments

Country Status (6)

Country Link
EP (1) EP1263472A2 (fr)
JP (1) JP2003522806A (fr)
AU (1) AU2001238346A1 (fr)
CA (1) CA2400205A1 (fr)
IL (1) IL151024A0 (fr)
WO (1) WO2001060412A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0116803A (pt) * 2001-01-18 2004-02-17 Merck Patent Gmbh Proteìnas de fusão bifuncionais com atividade de glicocerebrosidase
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
WO2004060404A1 (fr) * 2002-12-27 2004-07-22 Chugai Seiyaku Kabushiki Kaisha Vecteur de medicament
US7803386B2 (en) 2003-06-05 2010-09-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
CA2529486A1 (fr) * 2003-06-18 2004-12-23 Nst Neurosurvival Technologies Ltd. Procede destine au ciblage selectif de cellules apoptotiques et ligands a petites molecules utilises dans ce but
JP2007509643A (ja) * 2003-10-10 2007-04-19 ゲ・ミン・ルイ 角膜内皮および関連細胞のバイオポリマー上での増殖のための方法および組成物ならびに人工角膜移植片の作成
US7625736B2 (en) 2004-06-04 2009-12-01 The United States Of America As Represented By The Department Of Health And Human Services Methods for preparing immunogenic conjugates
EP1790665B1 (fr) 2004-09-07 2014-11-05 Chugai Seiyaku Kabushiki Kaisha Procedé de production d'acide hyaluronique modifié soluble dans l'eau
JP5137814B2 (ja) * 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート
US20080206276A1 (en) 2005-07-08 2008-08-28 Michael Otto Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections
PT2121713E (pt) 2007-01-18 2013-06-25 Genzyme Corp Oligossacáridos compreendendo um grupo aminooxi e seus conjugados
EP2465542B1 (fr) 2008-12-16 2015-01-21 Genzyme Corporation Conjugues Oliogosaccharide-Proteine
ES2635087T3 (es) 2011-03-03 2017-10-02 Chugai Seiyaku Kabushiki Kaisha Derivado de ácido hialurónico modificado con ácido amino-carboxilico
WO2012140650A2 (fr) 2011-04-12 2012-10-18 Hepacore Ltd. Conjugués de carboxy polysaccharides avec des facteurs de croissance des fibroblastes et variants de ceux-ci
KR102130864B1 (ko) 2012-09-05 2020-07-08 추가이 세이야쿠 가부시키가이샤 아미노산 및 스테릴기가 도입된 히알루론산 유도체
KR102049568B1 (ko) * 2013-04-01 2019-11-27 삼성전자주식회사 히알루론산을 포함하는 핵산전달용 조성물
GB201602359D0 (en) * 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108440684A (zh) * 2018-03-22 2018-08-24 华侨大学 一种NI-Cys-Alg自组装纳米载体及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0537299A1 (fr) 1990-03-29 1993-04-21 Gilead Sciences, Inc. Conjugues a base de disulfure d'oligonucleotide et d'un agent de transport
US5169934A (en) 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds
US6335434B1 (en) * 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
CA2122717C (fr) 1991-11-08 2003-07-15 David C. Anderson Hemoglobines utilisees comme agents d'administration de medicaments
US5902795A (en) 1992-06-16 1999-05-11 Trustees Of Tufts College Oligosaccharides reactive with hyaluronan-binding protein and their methods of use
US5329029A (en) 1992-11-05 1994-07-12 Wan Barbara Y Phosphatidylalkanolamine derivatives and their use in generating phospholipid conjugates
AU673057B2 (en) * 1993-02-22 1996-10-24 Abraxis Bioscience, Llc Methods for (in vivo) delivery of biologics and compositionsuseful therefor
US5354853A (en) 1993-03-12 1994-10-11 Genzyme Corporation Phospholipid-saccharide conjugates
EP0975370B9 (fr) 1997-05-21 2004-11-03 The Board Of Trustees Of The Leland Stanford Junior University Composition et procede permettant d'ameliorer les transports a travers des membranes biologiques
US5932552A (en) 1997-11-26 1999-08-03 Keraplast Technologies Ltd. Keratin-based hydrogel for biomedical applications and method of production

Also Published As

Publication number Publication date
AU2001238346A1 (en) 2001-08-27
IL151024A0 (en) 2003-02-12
EP1263472A2 (fr) 2002-12-11
WO2001060412A3 (fr) 2002-01-24
JP2003522806A (ja) 2003-07-29
WO2001060412A2 (fr) 2001-08-23

Similar Documents

Publication Publication Date Title
US6749865B2 (en) Modification of biopolymers for improved drug delivery
AU2021201321B2 (en) Preparation and/or formulation of proteins cross-linked with polysaccharides
CA2400205A1 (fr) Modification de biopolymeres pour administration amelioree de medicaments
US5527893A (en) Water insoluble derivatives of polyanionic polysaccharides
US5874417A (en) Functionalized derivatives of hyaluronic acid
US7029688B2 (en) Methods and compositions to prevent formation of adhesions in biological tissues
US4937270A (en) Water insoluble derivatives of hyaluronic acid
US6174999B1 (en) Water insoluble derivatives of polyanionic polysaccharides
US6884788B2 (en) Thiol-modified hyaluronan
US6030958A (en) Water insoluble derivatives of hyaluronic acid
US6235726B1 (en) Water insoluble derivatives of polyanionic polysaccharides
EP0640622A1 (fr) Derive de polysaccharide et vehicule de medicament
WO1992000105A1 (fr) Derives d'acide hyaluronique insolubles dans l'eau
US20080292664A1 (en) Hydrogels and Hyaluronic Acid and Alpha, Beta-Polyaspartyl-Hydrazide and Their Biomedical and Pharmaceutical Uses
US20110262492A1 (en) Catalyst and byproduct-free native chemical ligation using cyclic thioester precursors
CA2140108A1 (fr) Conjugues de collagene et de polymeres synthetiques ayant une distribution regularisee de diametres des fibres
HK40009300A (en) Preparation and/or formulation of proteins cross-linked with polysaccharides

Legal Events

Date Code Title Description
FZDE Discontinued